Loading...
Loading...
AstraZeneca
AZN announced today that a combined panel of experts from
the American College of Cardiology Foundation (ACCF) and American Heart
Association (AHA) have updated their guidelines to include a Class I
recommendation for use of the oral antiplatelet (OAP) medicine BRILINTA^®
(ticagrelor) tablets in patients with ST-elevation myocardial infarction
(STEMI) managed invasively.^1 With this latest guidelines update, BRILINTA is
included in more than 10 major acute coronary syndrome (ACS) treatment
guidelines globally.^1-11
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in